RYTM
Rhythm·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RYTM
Rhythm Pharmaceuticals, Inc.
A commercial-stage biopharmaceutical company focused on the treatment of hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases
222 Berkeley Street, 12th Floor, Boston, MA 02116
--
Rhythm Pharmaceuticals, Inc., a Delaware corporation, was founded in February 2013. The company is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients and their families with rare neuroendocrine diseases. The company is focused on advancing melanocortin -4 receptor agonists, including their main asset, IMCIVREE, as a precision drug designed to treat hyperappetite and severe obesity caused by rare MC4R pathway diseases.
Earnings Call
Q1/2025
Estimate EPS-0.68
Actual EPS-0.81
Estimate Revenue40.16M
Actual Revenue32.70M
Rhythm Pharmaceuticals Q1 2025: Navigating Contradictions in Compliance, Revenue Forecasts, and FDA Expectations
May 12,2025 10:51
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.67
Actual EPS-0.75
Estimate Revenue43.64M
Actual Revenue48.50M
Rhythm Pharmaceuticals' Q2 2025: Navigating Key Contradictions in Trial Design, Stock Compensation, and Market Dynamics
Aug 05,2025 05:25
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
RYTM has released its 2025 Q3 earnings. EPS was reported at -0.82, versus the expected -0.73, missing expectations. The chart below visualizes how RYTM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RYTM has released its 2025 Q3 earnings report, with revenue of 51.30M, reflecting a YoY change of 54.28%, and net profit of -52.90M, showing a YoY change of -21.23%. The Sankey diagram below clearly presents RYTM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
